Free Trial
OTCMKTS:DSNKY

Daiichi Sankyo 4/25/2025 Earnings Report

Daiichi Sankyo logo
$26.89 +0.55 (+2.09%)
As of 05/27/2025 03:59 PM Eastern

Daiichi Sankyo EPS Results

Actual EPS
$0.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Daiichi Sankyo Revenue Results

Actual Revenue
$3.40 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Daiichi Sankyo Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Earnings Headlines

Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
DSKYF Daiichi Sankyo Company, Limited
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

View Daiichi Sankyo Profile

More Earnings Resources from MarketBeat